Company

Reunion Neuroscience Inc.

Reunion Neuroscience develops psychedelic-based treatments for mental health conditions.

About

Founded in 2022 and based in Ontario, Canada, Reunion Neuroscience is a clinical-stage biopharmaceutical company developing treatments for mental health conditions. Its pharmaceutical research includes psychedelic compounds for psychiatric conditions such as depression. In May 2023, MPM Capital agreed to acquire the company for USD 13.1 million in cash or USD 1.12 per share. At that time, it was listed on NASDAQ under ticker REUN and led by President and CEO Greg Mayes.

2Funding rounds

4Investors

Sign in to see more

Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.

Sign in